Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection

Taniguchi, Keiichi; Ando, Yoshinori; Kobayashi, Masanori; Toba, Shinsuke; Nobori, Haruaki; Sanaki, Takao; Noshi, Takeshi; Kawai, Makoto; Yoshida, Ryu; Sato, Akihiko; Shishido, Takao; Naito, Akira; Matsuno, Keita; Okamatsu, Masatoshi; Sakoda, Yoshihiro; Kida, Hiroshi

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection

Taniguchi, Keiichi; Ando, Yoshinori; Kobayashi, Masanori et al.

Viruses-Basel, 2022, 14(1), 111

Permalink : https://hdl.handle.net/2115/84183

このアイテムのアクセス数:463件（2026-10-09 20:30 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.3390/v14010111			32

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/84183
タイトル	Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
著者	Taniguchi, Keiichi ; Ando, Yoshinori ; Kobayashi, Masanori ; Toba, Shinsuke ; Nobori, Haruaki ; Sanaki, Takao ; Noshi, Takeshi ; Kawai, Makoto ; Yoshida, Ryu ; Sato, Akihiko ; Shishido, Takao ; Naito, Akira ; Matsuno, Keita ; Okamatsu, Masatoshi ; Sakoda, Yoshihiro ; Kida, Hiroshi
著者名 Taniguchi, Keiichi
著者名 Ando, Yoshinori
著者名 Kobayashi, Masanori
著者名 Toba, Shinsuke
著者名 Nobori, Haruaki
著者名 Sanaki, Takao
著者名 Noshi, Takeshi
著者名 Kawai, Makoto
著者名 Yoshida, Ryu
著者名 Sato, Akihiko
著者名 Shishido, Takao
著者名 Naito, Akira
e-Rad_Researcher 40753306 著者名 Matsuno, Keita
e-Rad_Researcher 00507163 著者名 Okamatsu, Masatoshi
e-Rad_Researcher 40333637 著者名 Sakoda, Yoshihiro
e-Rad_Researcher 10109506 著者名 Kida, Hiroshi
言語	英語
キーワード	baloxavir marboxil
	viral replication
	inhibition
	lung inflammation
	combination therapy
	oseltamivir
発行日	2022-01
出版者	MDPI
収録物名	Viruses-Basel
巻(号)	14(1)
ページ	111
抄録	Human infections caused by the H5 highly pathogenic avian influenza virus (HPAIV) sporadically threaten public health. The susceptibility of HPAIVs to baloxavir acid (BXA), a new class of inhibitors for the influenza virus cap-dependent endonuclease, has been confirmed in vitro, but it has not yet been fully characterized. Here, the efficacy of BXA against HPAIVs, including recent H5N8 variants, was assessed in vitro. The antiviral efficacy of baloxavir marboxil (BXM) in H5N1 virus-infected mice was also investigated. BXA exhibited similar in vitro activities against H5N1, H5N6, and H5N8 variants tested in comparison with seasonal and other zoonotic strains. Compared with oseltamivir phosphate (OSP), BXM monotherapy in mice infected with the H5N1 HPAIV clinical isolate, the A/Hong Kong/483/1997 strain, also caused a significant reduction in viral titers in the lungs, brains, and kidneys, thereby preventing acute lung inflammation and reducing mortality. Furthermore, compared with BXM or OSP monotherapy, combination treatments with BXM and OSP using a 48-h delayed treatment model showed a more potent effect on viral replication in the organs, accompanied by improved survival. In conclusion, BXM has a potent antiviral efficacy against H5 HPAIV infections.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	1999-4915
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.3390/v14010111